Cytori Therapeutics Inc (NASDAQ:CYTX) shares saw an uptick in trading volume on Thursday . 4,305,355 shares changed hands during mid-day trading, an increase of 37% from the previous session’s volume of 3,141,875 shares.The stock last traded at $0.42 and had previously closed at $0.42.

Several brokerages have recently weighed in on CYTX. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, January 5th. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

The company has a market cap of $13.46, a PE ratio of -0.45 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. During the same quarter in the prior year, the company earned ($0.26) EPS. analysts forecast that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.90% of the stock is owned by corporate insiders.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC boosted its position in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,626,807 shares of the biotechnology company’s stock after acquiring an additional 355,504 shares during the period. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent SEC filing. Institutional investors own 7.41% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cytori Therapeutics (CYTX) Sees Unusually-High Trading Volume” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.